投資五千萬元醫藥物流商裕利首推健康解決方案(ZHS) 民眾網 2017/07/17【記者羅博特台北報導】日前,
Pages
Tuesday, July 18, 2017
(新加坡) 裕利醫藥物流 成立 "健康解決創新中心"
健字號食品 將限制 "精緻糖" 量 !!
健康食品太甜 食藥署訂限量 2017年07月17日【記者施芝吟/綜合報導】
台灣 國光流感疫苗 正式中國上市 (三價疫苗)
台灣生產流感疫苗正式登陸 國光生技供應 發稿時間:2017/07/17(中央社記者田裕斌台北17日電
泰合 galantamine貼片(阿茲海默症藥) TAH8801 數據發表!
泰合阿茲海默氏症貼片 將發表臨床數據 2017-07-18 05:51經濟日報 記者黃文奇╱即時報導泰合(6467)宣布,該公司16日至19
安成生技 AC-203授權Castle Creek Pharmaceuticals 美歐拚藥證(2018Q4)
安成生營運報喜 拚年底送件申請上櫃 杜蕙蓉/台北報導 2017/07/18安成生技(6610)受惠罕病新藥AC-
全球 整形 TOP 6: 隆乳、抽脂、眼皮、整鼻、腹拉皮、臉脂肪注射
女性私密處整形大增 台灣醫美關注 2017-07-14 16:12中央社 高雄14日電 國際美容外科醫學會一項全球統計,全球陰唇整形成長量首度躍居整
景澤生技 涉嫌 重新改標 (謝姓負責人已離境)
改保健品效期 檢方偵辦景澤生技 2017年07月14日 【記者陳懿勝/綜合報導】
美醫特管法 醫界質疑?!
積極把關美醫亂象元凶 提升台灣醫療競爭力2017-07-14健康醫療網/
看似立意良善 反陷本末倒置 因此,政府為積極管理美醫亂象,在2015年12月29公告行政
美醫糾紛 低價不實廣告是肇始 根據各縣市衛生局之美容醫學醫療糾紛案件統計,
美容醫學相關學會自律 專業與實務並進 因此,多數非部定的醫學會,如台灣顏面整形重建外科醫學會、
管控不實誇大廣告 保障民眾醫權 醫界呼籲政府針對美容醫學的亂象,
柏登 現增1.8億 (15元/股)
柏登 發言日期 106/07/14 發言時間 17:46:54 發言人 賴弘基 發言人職稱 董事長兼總經理 發言人電話 +886226597698 主旨 公告本公司訂定106年現金增資認股基準日 符合條款 第9款 事實發生日 106/07/14 說明 1.董事會決議或公司決定日期:106/07/14 2.發行股數:12,000,000股 3.每股面額:10元 4.發行總金額:120,000,000元 5.發行價格:每股新台幣15元 6.員工認購股數:依公司法第267條規定保留15%,計1,
天良生技 2.1億 處分 合誠化學製藥 (21元/股)
天良生技 發言日期 106/07/14 發言時間 18:32:44 發言人 陳雋奇 發言人職稱 財務處經理 發言人電話 02-26483099#5931 主旨 公告本公司董事會通過處分子公司合誠化學製藥股份有限公司 全數股權予好安國際有限公司 符合條款 第20款 事實發生日 106/07/14 說明 1.標的物之名稱及性質(屬特別股者,
天良生技 (董事長/總經理) 沈錫聰 退/ 紀元章 接
天良生技 發言日期 106/07/14 發言時間 18:33:06 發言人 陳雋奇 發言人職稱 財務處經理 發言人電話 02-26483099分機5931 主旨 公告本公司董事會通過總經理任命案 符合條款 第6款 事實發生日 106/07/14 說明 1.董事會決議日期或發生變動日期:106/07/14 2.人員別(請輸入董事長或總經理):總經理 3.舊任者姓名及簡歷:沈錫聰-
健亞 晉升年輕人當 總經理/ 陳正 轉任 策略長 (董事長)
106/07/05 4.新任者姓名、級職及簡歷:陳正/健亞生物科技(股)公司董事
(2015經濟學人智庫) 全球臨終安寧照護: 台灣 亞洲第1/全球第6
陳建仁:台灣安寧醫療亞洲第一【大紀元2017年07月15日訊
FDA同意 逸達 長效 Leuprolide (3-month)phase III (open label, IND 134405 )
逸達 發言日期 106/07/16發言人 周珮芬 發言人職稱 財務長 發言人電話 (02)2655-2658 主旨 本公司前列腺癌新劑型新藥FP-001 25毫克通過美國食品 藥物管理局(FDA)之新藥臨床試驗(IND),
(JCI) PM2.5增加 提升"肝"癌 死亡率/ WHO認定 PM2.5: 一級致癌物質
PM2.5高空品差 肝癌死亡率多10倍 2017年07月16日作者 胸腔重症醫師 蘇一峰 多年來肺癌與肝癌一直是台灣第一與第二名的癌症死亡原因,
肺癌也會受影響 令人驚訝的是,研究發現居住於空氣差的肝癌患者,
須持續關切空污 過去癌症患者的治療,我們常注重於藥物治療、開刀、
FDA全票通過 Novartis基因治療 (CAR-T : CTL019 for pediatric, young adult r/r B-cell ALL)
FDA委员会建议批准白血病的基因疗法本周三美国食药监(
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Basel, July 12, 2017 - Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). "The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need," said Bruno Strigini, CEO, Novartis Oncology. "We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and young adults with r/r B-cell ALL and other critically ill patients who have limited options. We look forward to working with the FDA as they complete their review." Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children under 15 years old and is the most common childhood cancer in the US[1]. Effective treatment options for patients with r/r ALL are limited. In pediatric and young adult patients with B-cell ALL that have relapsed multiple times or become refractory to treatment, the five-year disease-free survival is less than 10-30%[2],[3],[4]. The ODAC recommendation is based on review of the CTL019 r/r B-cell ALL development program, which includes the Novartis-led ELIANA study (NCT02435849), the first pediatric global CAR-T cell therapy registration trial. Findings from a US multicenter trial and a single site trial examining the safety and efficacy of CTL019 among pediatric and young adult patients with r/r B-cell ALL also supported the recommendation and the Biologics License Application (BLA)[5]. CTL019 was first developed by the University of Pennsylvania (Penn) and uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular responses as well as persistence of CTL019 after it is infused into the patient, which may be associated with long-lasting remissions in patients. In 2012, Novartis and Penn entered into a global collaboration to further research, develop and commercialize CAR-T cell therapies, including CTL019, for the investigational treatment of cancers. Children's Hospital of Philadelphia (CHOP) was the first institution to investigate CTL019 in the treatment of pediatric patients and led the single site trial. "It is encouraging to see the FDA panel's recommendation and continued momentum behind this innovative therapy, which has potential to help young patients with relapsed/refractory B-cell ALL," said the Penn team's leader, Carl June, MD, the Richard W. Vague Professor of Immunotherapy, director of the Center for Cellular Immunotherapies in Penn's Perelman School of Medicine and director of the Parker Institute for Cancer Immunotherapy at Penn. "We look forward to continuing to work with Novartis to help make a lasting impact on the way this disease is treated." "We know firsthand from treating children and young adults with relapsed/refractory B-cell ALL that they desperately need innovative medicines that provide a new approach to managing this aggressive disease," said Stephan Grupp, MD, PhD, the Yetta Deitch Novotny Professor of Pediatrics at the Perelman School of Medicine at Penn, Director of the Cancer Immunotherapy Frontier Program and Chief of the Section of Cellular Therapy and Transplant at CHOP. "Today's vote in favor of CTL019 is a positive step and we appreciate Novartis' commitment to pediatric patients." Earlier this year, Novartis submitted a BLA for CTL019 to the FDA, marking the first submission by Novartis for a CAR-T cell therapy. CTL019 previously received FDA Breakthrough Therapy designation and is under Priority Review by the FDA. The FDA will consider the vote as it reviews the BLA, although it is not obligated to follow the recommendation. Novartis continues to invest in the necessary infrastructure for the potential commercialization of CTL019, including manufacturing and the establishment of a network of certified treatment centers. Novartis plans additional filings for CTL019 in the US and EU later this year, including applications with the FDA and European Medicines Agency (EMA) for the treatment of adults with r/r diffuse large B-cell lymphoma (DLBCL).
About CAR-T and CTL019 CAR-T is different from typical small molecule or biologic therapies because it is manufactured for each individual patient using their own cells. During the treatment process, T cells are drawn from a patient's blood and reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other B-cells expressing a specific antigen. ELIANA (NCT02435849) is the first pediatric global CAR-T cell therapy registration trial, with study enrollment having occurred across 25 centers in the US, Canada, EU, Australia and Japan. Because CTL019 is an investigational therapy, the safety and efficacy profile has not yet been established. Access to investigational therapies is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the therapy. Because of the uncertainty of clinical trials, there is no guarantee that CTL019 will ever be commercially available anywhere in the world.
About CTL019 Manufacturing The Novartis leukapheresis process using cryopreservation allowed for manufacturing and treatment of patients from around the world. Cryopreserved leukapheresis involves removing white blood cells from a patient's blood and preserving them at very low temperatures. Cryopreserved leukapheresis gives physicians the flexibility to schedule apheresis at a time that is in the best interest of their patients. Novartis commercial manufacturing for CTL019 continues to build on its experience in its Morris Plains, New Jersey facility, which has already manufactured CTL019 for hundreds of patients in global clinical trials. Novartis believes that experience is important in cell therapy manufacturing, and the experience gained at the Morris Plains, New Jersey facility will be a foundation for commercial manufacturing of CAR-T therapies. Novartis has made and continues to make investments in manufacturing.
References
[1] Howlader, N., Noone, A.. M, Krapcho, M., et al. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute, April 2013; Section 28.9 (12).
[2] Oudot, C.., Auclerc, F.., Levy, V., et al. Prognostic Factors for Leukemia Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study. Journal of Clinical Oncology, March 2008; Volume 28 (9).
[3] Chessels, J., Veys, P., Kempski, H., et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. British Journal of Hematology, 2003; 123 (3).
[4] Reismuller, B., Peters, C., Dworzak, M., et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Journal of Pediatric Hematology/Oncology. July 2013; 35 (5).
[5] Novartis CTL019 ODAC Briefing Document.
(永齡基金會) H. Spectrum青年翻轉培訓計畫+馬偕 黃明源 醫師 進軍TRANS Conference 2017
永齡生醫新創競賽3團隊勝出 2017年07月16日18:37永齡健康基金會發起的第二屆「